Perrigo rises as FDA advisers back OTC use of birth control pill

Perrigo

10/05/2023 19:09

** Shares of Perrigo Company PLC  PRGO.N  up 2.8% at $35.84
    ** A U.S. FDA advisory panel unanimously voted in favor of
the over-the-counter (OTC) use of the drugmaker's birth control
pill
    ** The decision comes after the FDA reviewers on Friday
raised concerns around allowing daily OTC use of Opill, saying
switching to non-prescription sale could lead to inappropriate
usage by consumers
    ** Perrigo's Opill, currently approved for prescription use,
would be the first OTC non-estrogen contraceptive pill in the
U.S., if approved by the health regulator
    ** FDA generally follows the advise of its experts, though
it is not bound to do so
    ** FDA panel positive on the pill's effectiveness, not only
in the general population of women but also in adolescent
populations and those with limited literacy
    ** Including session moves, PRGO stock up ~5% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))